Nanostring Unveils Its Molecular Diagnostics Strategy

One strategy for growth among analytical platform companies is to leverage its instrumentation sales channel by developing or acquiring diagnostics content. Nanostring is now doing this by in-licensing a gene expression signature for breast tumor typing. And unlike other molecular tests for guiding breast cancer therapy, which are performed in specialty CLIA labs run by their developers, this one will be broadly distributed to hospitals and pathology laboratories globally.